Loading
The first drug ever to extend life in metastatic uveal melanoma, and the first T-cell receptor-based medicine to win a phase 3.
IMCgp100-202, trial NCT03070392 sponsored by Immunocore and reported in 2021, produced the first drug ever to extend life in metastatic uveal melanoma and the first T-cell receptor-based medicine to win a phase 3. It randomised 378 untreated HLA-A*02:01-positive patients to tebentafusp or investigator's choice of pembrolizumab, ipilimumab or dacarbazine and met its primary overall survival endpoint despite a low response rate, showing that circulating tumour DNA reduction and slowed growth matter more than RECIST shrinkage for this class; approval followed in January 2022, with cytokine release syndrome and rash manageable through step-up dosing. There is no second randomised trial, and whether the approach transfers to cutaneous melanoma, as PRISM-MEL-301 tests, is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
A second publication from the IMCgp100-202 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT03070392 with the most citations, so it is the natural first reading for anyone following the IMCgp100-202 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma, Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma, Tebentafusp, T-cell engagers (bispecific).
Shares Immunocore, Tebentafusp, T-cell engagers (bispecific), Melanoma.
Shares Immunocore, CD3, T-cell engagers (bispecific), Melanoma.
Shares Immunocore, Tebentafusp, T-cell engagers (bispecific).
Shares Immunocore, Tebentafusp, CD3, T-cell engagers (bispecific).
Shares Immunocore, Tebentafusp, T-cell engagers (bispecific).
Shares gp100 (PMEL), Tebentafusp, CD3, Melanoma.
Shares gp100 (PMEL), Immunocore, Tebentafusp, T-cell engagers (bispecific).